A new study has revealed how a strain of E. coli acquired the ability to resist a range of antibiotics, including colistin, which is considered a last-resort treatment for drug-resistant infections.

The study, which was published in the journal Nature Microbiology, found that the E. coli strain acquired a gene called mcr-1, which encodes an enzyme that can break down colistin. The gene was found to have been transferred to E. coli from a different type of bacteria called Klebsiella pneumoniae.

The researchers believe that the transfer of the mcr-1 gene occurred in a hospital setting, where both E. coli and Klebsiella pneumoniae are common pathogens. They also found that the E. coli strain had acquired other genes that confer resistance to a range of other antibiotics, including ampicillin, ceftazidime, and ciprofloxacin.

This study highlights the serious threat posed by antibiotic resistance and the need for new strategies to combat it.

Key findings of the study:

- The E. coli strain acquired the mcr-1 gene from Klebsiella pneumoniae through horizontal gene transfer.

- The E. coli strain also acquired other genes that confer resistance to a range of other antibiotics.

-The study highlights the serious threat posed by antibiotic resistance and the need for new strategies to combat it.

Implications of the study:

The findings of this study have several implications for public health:

- The spread of antibiotic resistance genes between different types of bacteria is a serious concern, as it can make it more difficult to treat infections.

- The emergence of colistin-resistant E. coli is a particular concern, as colistin is considered a last-resort treatment for drug-resistant infections.

- New strategies are needed to combat antibiotic resistance, such as developing new antibiotics and finding ways to prevent the spread of resistance genes between bacteria.